Figure 2. Unadjusted Cumulative Incidence of All-Cause Mortality (ACM) and Cumulative Incidence Function of Prostate Cancer–Specific Mortality (PCSM) After Accounting for Competing Risk .

Includes the 139 patients with performance status of 0, comparing patients in the standard of care (SOC) group with those in the SOC plus docetaxel group. For ACM, log-rank P = .03. For PCSM, Gray P = .007.